[Pembrolizumab (gastric and gastro-oesophageal junction adenocarcinoma, HER2-positive) – Addendum to Project A24-01]
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018013137
German
Original Title:
Pembrolizumab (Adenokarzinom des Magens oder des gastroösophagealen Übergangs, HER2-positiv)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a24-58.html
Year Published:
2024
URL for published report:
https://www.iqwig.de/download/a24-58_pembrolizumab_addendum-zum-projekt-a24-01_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Esophageal Neoplasms
- Stomach Neoplasms
- Antibodies, Monoclonal, Humanized
- Immune Checkpoint Inhibitors
- Antineoplastic Agents, Immunological
Keywords
- Pembrolizumab
- Stomach Neoplasms
- Esophageal Neoplasms
- Benefit Assessment
- NCT03615326
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.